Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 21571797.
- Also identified by DOI 10.2967/jnumed.110.084236.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiolabeled peptides have been an important class of compounds in radiopharmaceutical sciences and nuclear medicine for more than 20 years. Despite strong research efforts, only somatostatin-based radiopeptides have a real impact on patient care, diagnostically and therapeutically. [(111)In-diethylenetriaminepentaacetic acid(0)]octreotide is commercially available for imaging. Imaging was highly improved by the introduction of PET radionuclides such as (68)Ga, (64)Cu, and (18)F. Two peptides are successfully used in targeted radionuclide therapy when bound to DOTA and labeled with (90)Y and (177)Lu.
Medical subject headings
- Neoplasms
- Radioisotopes
- Radionuclide Imaging
- Radiotherapy
- Receptors, Somatostatin